Sofosbuvir and ribavirin in HCV genotypes 2 and 3.Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; VALENCE Investigators.
N Engl J Med. 2014 May 22;370(21):1993-2001.
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B.
N Engl J Med. 2014 Apr 24;370(17):1604-14.
Faldaprevir and deleobuvir for HCV genotype 1 infection.Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Böcher WO, Mensa FJ.
N Engl J Med. 2013 Aug 15;369(7):630-9.
Telaprevir for retreatment of HCV infection.Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team.
N Engl J Med. 2011 Jun 23;364(25):2417-28.
Telaprevir for previously untreated chronic hepatitis C virus infection.Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS,
Zeuzem S; ADVANCE Study Team.
N Engl J Med. 2011 Jun 23;364(25):2405-16.
Peginterferon alfa-2a in patients with chronic hepatitis C.Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ.
N Engl J Med. 2000 Dec 7;343(23):1666-72.